Short Communication, J Otol Rhinol Vol: 12 Issue: 5
The Causes and Management of Laryngeal Neoplasms
Alessandra Marioni*
1Department of Otolaryngology, University of Udine, Udine, Italy
*Corresponding Author: Alessandra Marioni,
Department of Otolaryngology,
University of Udine, Udine, Italy
E-mail: marionialessandra@gmail.com
Received date: 18 August, 2023, Manuscript No. JOR-23-118331;
Editor assigned date: 21 August, 2023, PreQC No. JOR-23-118331 (PQ);
Reviewed date: 04 September, 2023, QC No. JOR-23-118331;
Revised date: 11 September, 2023, Manuscript No. JOR-23-118331 (R);
Published date: 18 September, 2023, DOI: 10.4172/2324-8785.100072
Citation: Marioni A (2023) The Causes and Management of Laryngeal Neoplasms. J Otol Rhinol 12:4.
Description
Laryngeal neoplasms, or tumors of the larynx, are a significant concern in the field of otolaryngology. These neoplasms can range from benign growths to malignant cancers, and their impact on voice and respiratory function can be profound.
Laryngeal neoplasms encompass a diverse group of tumors that arise within the larynx, an essential structure for vocalization and airway protection. While some laryngeal growths are benign and nonlife- threatening, others can be malignant and pose a serious threat to a patient's health and quality of life. Understanding the intricacies of laryngeal neoplasms is crucial for both healthcare professionals and patients. This manuscript aims to shed light on the various aspects of laryngeal neoplasms, including their causes, types, clinical presentation, diagnostic procedures, and treatment options [1].
Etiology
The development of laryngeal neoplasms is multifactorial, with both genetic and environmental factors playing a significant role. Smoking and excessive alcohol consumption are well-established risk factors for laryngeal cancer. Human Papillomavirus (HPV) infection has also been linked to some cases of laryngeal cancer, particularly in younger patients. Additionally, exposure to industrial agents, such as asbestos and wood dust, can contribute to the development of laryngeal tumors [2,3].
Classification
Laryngeal neoplasms can be broadly classified into two categories: benign and malignant. Benign neoplasms, such as papillomas or cysts, typically cause voice changes and breathing difficulties but are noncancerous. On the other hand, malignant laryngeal neoplasms, including squamous cell carcinoma, adenocarcinoma, and sarcomas, are potentially life-threatening and require aggressive treatment [4].
Clinical presentation
The clinical presentation of laryngeal neoplasms can vary depending on the location, size, and type of the tumor. Common symptoms include hoarseness, a persistent cough, throat pain, difficulty swallowing, and stridor. Benign neoplasms may cause voice changes and mild discomfort, while malignant tumors often present with more severe symptoms, including weight loss and the presence of neck lymph nodes [5-7].
Diagnosis
The diagnosis of laryngeal neoplasms begins with a thorough medical history and physical examination. Otolaryngologists often use laryngoscopy, a procedure that allows for direct visualization of the larynx, to assess the extent of the tumor. Imaging studies like CT scans and MRIs can help determine the tumor's size and its relationship to nearby structures. A biopsy is performed to confirm the tumor's histological type, whether it is benign or malignant [8,9].
Treatment
The choice of treatment for laryngeal neoplasms depends on the tumor's type, stage, and the patient's overall health. Treatment options may include:
• Surgery: Benign neoplasms are often treated with surgical removal. In the case of malignant tumors, surgery may involve partial or total laryngectomy.
• Radiation therapy: Radiation therapy is commonly used as a primary treatment for early-stage laryngeal cancer or as an adjuvant therapy following surgery.
• Chemotherapy: Chemotherapy may be used in combination with radiation therapy for advanced laryngeal cancer. Targeted therapies and immunotherapies are emerging as potential treatment options.
• Voice rehabilitation: After treatment, many patients require voice rehabilitation to regain functional speech and swallowing abilities.
Laryngeal neoplasms encompass a wide spectrum of tumors, ranging from benign growths to malignant cancers. These tumors have a significant impact on an individual's voice and respiratory function. Early diagnosis and appropriate treatment are essential for the best possible outcomes. A multidisciplinary approach involving otolaryngologists, oncologists, radiologists, and speech therapists is crucial to providing comprehensive care to patients with laryngeal neoplasms. Further research into the etiology, prevention, and treatment of laryngeal neoplasms is ongoing, holding promise for improved outcomes and quality of life for affected individuals [10].
References
- Megwalu UC, Sikora AG (2014) Survival outcomes in advanced laryngeal cancer. JAMA Otolaryngol. Head Neck Surg 140(9): 855-860.
[Crossref] [Google Scholar] [Indexed]
- Forastiere AA, Ismaila N, Lewin JS, Nathan CA, Adelstein DJ, et al. (2018) Use of larynx-preservation strategies in the treatment of laryngeal cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 36(11): 1143-1169.
[Crossref] [Google Scholar] [Indexed]
- Sacco AG, Cohen EE (2015) Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma. J Clin Oncol 33(29): 3305-3313.
[Crossref] [Google Scholar] [Indexed]
- Szturz P, Vermorken JB (2017) Immunotherapy in head and neck cancer: Aiming at EXTREME precision. BMC Med 15 110.
[Crossref] [Google Scholar] [Indexed]
- Mann JE, Smith JD, Birkeland AC, Bellile E, Swiecicki P, et al. (2019) Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma. Cancer Immunol Immunother 68(2): 213-220.
[Crossref] [Google Scholar] [Indexed]
- Spector ME, Bellile E, Amlani L, Zarins K, Smith J, et al. (2019) Prognostic value of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 145(11): 1012-1019.
[Crossref] [Google Scholar] [Indexed]
- Ferris RL (2015) Immunology and immunotherapy of head and neck cancer. J Clin Oncol 33(29): 3293–3304.
[Crossref] [Google Scholar] [Indexed]
- Sivan A, Corrales L, Hubert N, Williams JB, Michaels KA, et al. (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350(6264): 1084-1089.
[Crossref] [Google Scholar] [Indexed]
- Wu Y, Chen W, Xu ZP, Gu W (2019) PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol 10: 2022.
[Crossref] [Google Scholar] [Indexed]
- Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, et al. (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462(7269): 108–112.
[Crossref] [Google Scholar] [Indexed]